Krystal Biotech's decision date for experimental treatment drug receives 3-month delay from FDA
January 09, 2023 at 15:34 PM EST
Krystal's candidate to treat dystrophic epidermolysis bullosa candidate, which is sometimes referred to as "butterfly child" due to the fragile-like conditions that become of the skin as a result of the disease, has seen a delay.
